Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
Inclusion Criteria
- Patients must have a diagnosis of chronic phase chronic myeloid leukemia without any history of progression to accelerated or blast phase CML; no new bone marrow aspiration and biopsy is needed to prove diagnosis prior to randomization; however, documentation stating the patient is in chronic phase is required
- Patients must have detectable BCR-ABL transcripts measured by reverse transcriptase (RT)-PCR at a clinical laboratory improvement act (CLIA)-approved laboratory and reported on the international scale (IS) with a value of > 0.0032% IS and =< 1.0% IS within 21 days prior to randomization; the RT-PCR assay must have the sensitivity to detect a 4.5 log reduction in BCR-ABL transcripts from 100% IS (0.0032% IS or lower)
- Patients must have been receiving TKI treatment for CML for at least 12 months prior to randomization
- Patients must be currently receiving treatment with bosutinib (within the allowable dose range of 200-500 mg daily), nilotinib (within the allowable dose range of 150-400 mg BID or a cumulative daily dose of 300-800 mg), or dasatinib (within the allowable dose range of 40-140 mg daily); they must have received their current TKI for a minimum of 6 months prior to randomization and must be expected to remain on the same TKI for the next 12 months
- Patient must not have a history of resistance to any prior TKI drug; if patient has received more than one TKI, the reason for changing treatment must have been intolerance to the prior TKI and the treatment change must have occurred >= 6 months prior to randomization
- Patients must not be receiving any other investigational agents
- Patients must have complete history and physical examination within 28 days prior to randomization
- If clinically indicated, patients must have corrected Fridericia's correction formula (QTcF) interval < 500 ms (by Fridericia calculation) on a 12-lead electrocardiography (EKG) within 7 days prior to randomization
- Platelets >= 100,000/mm^3 (100.0 x 10^9/L) within 7 days prior to randomization
- Absolute neutrophil count (ANC) > 1,000/mm^3 (1.0 x 10^9/L) within 7 days prior to randomization
- Hemoglobin >= 8 g/dL within 7 days prior to randomization
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (IULN) within 7 days prior to randomization
- Total bilirubin =< 1.5 x IULN within 7 days prior to randomization (unless the patient has a known diagnosis of Gilbert’s syndrome)
- Serum creatinine =< 1.5 x IULN within 7 days prior to randomization
- Prior malignancy is allowed providing it does not require concurrent therapy; exception: active hormonal therapy is allowed
- Patients must not be pregnant or nursing due to the teratogenic potential of the drugs used on this study; women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to randomization; women/men of reproductive potential must have agreed to use an effective contraceptive method during treatment and for 30 days after discontinuation of study drug; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- Patients known to be human immunodeficiency virus positive (HIV+) are eligible provided they meet all other eligibility criteria and have undetectable HIV viral loads on their most recent viral load test which must have been performed in the last 6 months
- Specimens (peripheral blood) must be collected and submitted to a CLIA-approved laboratory, within 21 days prior to randomization; BCR-ABL transcripts must be measured using RT-PCR and results must be reported using the international scale; the RT-PCR assay must have the sensitivity to detect a 4.5 log reduction in BCR-ABL transcripts from 100% IS (must be able to detect 0.0032% IS or lower)
- Patients must be offered participation in submission of specimens for central BCR-ABL quantification and banking for future specimens; this submission is highly encouraged as an important protocol endpoint; with patient’s consent, specimens must be collected and submitted, within 21 days prior to randomization
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Alaska
Anchorage
Fairbanks
Arizona
Kingman
Phoenix
Arkansas
Ft. Smith
Hot Springs
California
Arroyo Grande
Burbank
San Luis Obispo
Santa Maria
Colorado
Aurora
Boulder
Centennial
Colorado Springs
Denver
Durango
Englewood
Golden
Grand Junction
Greeley
Lafayette
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Florida
Fort Lauderdale
Tampa
Hawaii
Aiea
Hilo
Honolulu
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Bloomington
Burr Ridge
Canton
Carthage
Centralia
Danville
Decatur
Dixon
Effingham
Eureka
Galesburg
Kewanee
Macomb
Mattoon
Maywood
Melrose Park
Mount Vernon
Orland Park
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Swansea
Urbana
Yorkville
Indiana
Fort Wayne
Iowa
Ames
Boone
Clive
Council Bluffs
Creston
Des Moines
Fort Dodge
Iowa City
Jefferson
Marshalltown
West Des Moines
Kansas
Garden City
Great Bend
Lawrence
Lenexa
Overland Park
Wichita
Kentucky
Bardstown
Corbin
Lexington
London
Louisville
Shepherdsville
Maryland
Baltimore
Massachusetts
Springfield
Michigan
Adrian
Ann Arbor
Battle Creek
Brighton
Canton
Caro
Chelsea
Clarkston
Detroit
East China
Flint
Grand Rapids
Grosse Pointe Woods
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Monroe
Muskegon
Niles
Norton Shores
Pontiac
Port Huron
Reed City
Rochester Hills
Saginaw
Saint Joseph
Sterling Heights
Tawas City
Traverse City
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Bemidji
Burnsville
Cambridge
Coon Rapids
Edina
Fridley
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Princeton
Robbinsdale
Saint Louis Park
Saint Paul
Shakopee
Stillwater
Thief River Falls
Waconia
Willmar
Woodbury
Worthington
Wyoming
Mississippi
Grenada
New Albany
Oxford
Southhaven
Missouri
Ballwin
Bolivar
Branson
Cape Girardeau
Farmington
Independence
Jefferson City
Joplin
Kansas City
Rolla
Saint Joseph
Saint Louis
Springfield
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Mexico
Albuquerque
New York
Buffalo
Rochester
North Carolina
Durham
Hendersonville
North Dakota
Bismarck
Fargo
Ohio
Belpre
Chillicothe
Cincinnati
Columbus
Delaware
Dublin
Grove City
Lancaster
Mansfield
Marietta
Marion
Maumee
Mount Vernon
Newark
Perrysburg
Portsmouth
Toledo
West Chester
Westerville
Zanesville
Oklahoma
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Newberg
Ontario
Portland
Redmond
Pennsylvania
Allentown
Bethlehem
Danville
East Stroudsburg
Hazleton
Lewisburg
Lewistown
Pottsville
Scranton
Selinsgrove
State College
Wilkes-Barre
South Carolina
Boiling Springs
Easley
Gaffney
Greenville
Greer
Seneca
Spartanburg
Union
South Dakota
Sioux Falls
Tennessee
Chattanooga
Collierville
Hixson
Memphis
Ooltewah
Texas
Bryan
Utah
American Fork
Cedar City
Logan
Murray
Ogden
Provo
Riverton
Saint George
Salt Lake City
Washington
Aberdeen
Auburn
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Gig Harbor
Issaquah
Kennewick
Lacey
Lakewood
Longview
Port Townsend
Poulsbo
Puyallup
Renton
Seattle
Sedro-Woolley
Shelton
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Yelm
Wisconsin
Burlington
Fond Du Lac
Germantown
Grafton
Green Bay
Kenosha
Marinette
Milwaukee
New Richmond
Oshkosh
Racine
Sheboygan
Summit
Two Rivers
Wauwatosa
West Allis
Wyoming
Cheyenne
Cody
Sheridan
PRIMARY OBJECTIVE:
I. To compare the rate of molecular response 4.5 (MR4.5) after 12 months of combination therapy with ruxolitinib phosphate (ruxolitinib) plus a tyrosine-kinase inhibitor (TKI) (bosutinib, dasatinib, or nilotinib) versus a TKI alone, based on local polymerase chain reaction (PCR) testing to measure BCR-ABL transcripts in chronic phase chronic myelogenous leukemia (CML) patients with molecular evidence of disease.
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of each regimen in this patient population.
II. To estimate progression free survival and overall survival of each regimen in this patient population.
ADDITIONAL OBJECTIVES:
I. To describe patterns of MR4.5 and molecular response 4.0 (MR4.0) attainment and failure over the 3, 6, 9, and 12-month time points of each regimen in this patient population.
II. To evaluate drug compliance based on patient reported drug intake calendars in this patient population.
III. To describe the kinetics of response in this patient population (as measured by quantitative BCR-ABL/BCR ratio) in both arms over the 3, 6, 9, and 12-month time points.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive bosutinib orally (PO) daily or dasatinib PO daily or nilotinib PO twice daily (BID) on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years, and then annually up to 5 years.
Trial Phase Phase II
Trial Type Treatment
Lead Organization
SWOG
Principal Investigator
Kendra L Sweet
- Primary ID S1712
- Secondary IDs NCI-2017-02066
- Clinicaltrials.gov ID NCT03654768